FMP
NASDAQ
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
0.283 USD
-0.016 (-5.66%)
Valuation Date:
Sep 16, 2024 2:57 PM
Share Price on Valuation Date
$0.28
Stock Beta
4.814
Shares Outstanding
23942448